BNOS 2022 | Identifying genetic risks of gliomagenesis with Mendelian randomization

Zak Thornton, University of Bristol, Bristol, UK, describes findings from a study assessing novel drug targets associated with developing glioma. Mendelian randomization, which involves measuring genetic variation to evaluate causality in observational data, was employed to analyze an expression quantitative trait loci (eQTL) database. Three novel target genes were identified that modify the risk of gliomagenesis including the GALNT6 gene, which has been previously found to promote metastasis in lung cancer. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.